Table 1.
Patient characteristics
| Dose
(mg/kg) |
ID | Age | Sex | Tumor Type | No. of
Infusions |
Best
overall response |
Time to
progression (days) |
OS
(days) |
Treatment-
related AEs (All) |
Treatment-
related AEs (Grade 3–4) |
Treg
depletion |
| 0.1 | B-01 | 66 | M | Esophageal cancer (SCC) | 6 | PD | 42 | 96 | + | + | + |
| 0.1 | B-03 | 70 | F | NSCLC | 8 | PD | 63 | 422 | + | – | + |
| 0.1 | B-05 | 67 | M | Melanoma | 5 | PD | 28 | 73 | + | – | + |
| 0.1 | B-07 | 68 | F | Melanoma | 8 | PD | 77 | 77 | + | – | + |
| 0.1 | B-10 | 64 | F | Esophageal cancer (SCC) | 8 | PD | 63 | 249 | + | + | + |
| 0.1 | B-11 | 70 | M | Esophageal cancer (Other) | 4 | PD | 25 | 391 | + | + | NA |
| 0.1 | B-12 | 66 | M | Melanoma | 8 | PD | 76 | 150 | + | – | + |
| 0.1 | B-15 | 57 | M | NSCLC | 8 | PD | 67 | 77 | + | – | + |
| 0.1 | B-19 | 76 | M | NSCLC | 8 | SD | 63 | 92 | + | + | + |
| 0.1 | B-21 | 67 | M | Melanoma | 8 | PD | 77 | 91 | + | + | + |
| 0.1 | B-22 | 53 | F | Ovarian cancer | 8 | PD | 67 | 224 | + | + | + |
| 0.1 | B-23 | 61 | M | NSCLC | 8 | PD | 63 | 498 | + | + | + |
| 0.1 | B-24 | 70 | M | Gastric cancer | 8 | PD | 70 | 271 | + | – | + |
| 0.1 | B-26 | 85 | M | Gastric cancer | 2 | PD | 21 | 21 | + | – | + |
| 0.1 | B-28 | 71 | M | Mesothelioma | 4 | SD | 40 | 40 | – | – | + |
| 0.1 | B-32 | 65 | F | NSCLC | 8 | PD | 63 | 395 | + | – | + |
| 0.1 | B-33 | 63 | F | Ovarian cancer | 8 | PD | 69 | 77 | + | – | + |
| 0.1 | B-35 | 47 | F | Esophageal cancer (Other) | 4 | PD | 29 | 31 | + | – | + |
| 0.1 | B-37 | 65 | M | Esophageal cancer (SCC) | 9 | SD | 96 | 284 | + | – | + |
| 0.1 | B-39 | 59 | F | Esophageal cancer (SCC) | 14 | PD | 70 | 251 | + | + | + |
| 1.0 | B-02 | 65 | F | Ovarian cancer | 8 | PD | 66 | 413 | + | – | + |
| 1.0 | B-04 | 68 | F | Melanoma | 8 | PD | 79 | 142 | – | – | + |
| 1.0 | B-06 | 49 | M | Melanoma | 8 | PD | 56 | 233 | + | – | + |
| 1.0 | B-08 | 51 | F | Esophageal cancer (SCC) | 2 | PD | 27 | 93 | + | – | + |
| 1.0 | B-09 | 64 | M | Esophageal cancer (SCC) | 23 | PR | 491 | 511 | + | + | + |
| 1.0 | B-13 | 54 | F | Ovarian cancer | 8 | PD | 65 | 318 | + | – | + |
| 1.0 | B-14 | 68 | F | Gastric cancer | 4 | PD | 35 | 35 | – | – | + |
| 1.0 | B-16 | 57 | M | NSCLC | 3 | PD | 25 | 25 | + | + | NA |
| 1.0 | B-17 | 67 | M | Gastric cancer | 5 | PD | 47 | 47 | + | – | + |
| 1.0 | B-18 | 68 | M | NSCLC | 8 | PD | 62 | 65 | + | + | + |
| 1.0 | B-20 | 54 | M | SCLC | 8 | PD | 56 | 58 | + | – | + |
| 1.0 | B-25 | 61 | M | NSCLC | 8 | PD | 63 | 497 | + | – | + |
| 1.0 | B-27 | 64 | M | Esophageal cancer (SCC) | 5 | PD | 36 | 99 | + | + | + |
| 1.0 | B-29 | 45 | M | Gastric cancer | 8 | PD | 70 | 272 | + | – | + |
| 1.0 | B-30 | 77 | M | Esophageal cancer (SCC) | 8 | PD | 63 | 68 | + | – | + |
| 1.0 | B-31 | 68 | M | Mesothelioma | 10 | SD | 124 | 124 | + | + | + |
| 1.0 | B-34 | 65 | M | Esophageal cancer (Other) | 8 | PD | 81 | 88 | + | + | + |
| 1.0 | B-36 | 80 | M | Mesothelioma | 10 | SD | 160 | 168 | + | – | + |
| 1.0 | B-38 | 73 | F | Ovarian cancer | 8 | PD | 76 | 84 | + | – | + |
NSCLC: non-small cell lung cancer
SCLC: small cell lung cancer
SCC: squamous cell carcinoma
PD: progressive disease
SD: stable disease
PR: partial response
AEs: adverse events
NA: not assessed